Bionor Pharma ASA's Phase II Vacc-4x Data Published In The Lancet Infectious Diseases
2/11/2014 9:32:10 AM
More...
|
Bionor Pharma ASA Appoints Anker Lundemose New VP and CEO
1/29/2013 7:02:25 AM
More...
|
Bionor Pharma ASA Release: Final Regulatory Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial
12/5/2012 9:37:03 AM
More...
|
Bionor Pharma ASA Release: Analysis of Immune Responses in Patients Treated With Vacc-4x Supports Further Development
9/12/2012 10:05:37 AM
More...
|
Bionor Pharma ASA Release: Study of Vacc-4x Combined With Celgene (CELG)'s Revlimid® (lenalidomide) in HIV Patients With Impaired Immune System Approved to Begin
8/13/2012 8:48:18 AM
More...
|
Bionor Pharma ASA's Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic "Boosts" That Could Result in New Treatment Option for People Living With HIV/AIDS
7/20/2012 9:18:04 AM
More...
|
HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma ASA
7/17/2012 9:12:52 AM
More...
|
GLOBVAC Awards Bionor Pharma ASA US $1.7 Million to Advance Research Towards an HIV Cure Using Vaccine Vacc-4x
7/9/2012 8:56:57 AM
More...
|
Bionor Pharma ASA Release: International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5
6/7/2012 9:01:03 AM
More...
|
Bionor Pharma ASA Release: International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus
6/7/2012 8:58:30 AM
More...
|
|